Association of an interleukin 1α polymorphism with Alzheimer’s disease
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Retrospective epidemiologic studies suggest that individuals exposed to anti-inflammatory agents such as nonsteroidal anti-inflammatory drugs have a lower probability of developing AD as well as an older age at onset for the illness. Neuroinflammation may play an important role in the pathogenesis of AD. Interleukin 1 (IL-1), a potent proinflammatory cytokine, is colocalized immunohistochemically to neuritic plaques, a requisite neuropathologic feature for AD. A polymorphism in the 5'-flanking regulatory region at -889 of the IL-1 alpha gene (a C-to-T transition designated as IL-1A[-889] allele 2) may cause an overexpression of IL-1 alpha, a finding shown to be associated with inflammatory diseases. The IL-1A(-889) allele 2 polymorphism may be associated with AD pathogenesis. METHODS: A total of 259 patients with AD and 192 nondemented control subjects were included from two different centers (Indianapolis, IN, and Munich, Germany). Genotyping for APOE alleles and IL-1A(-889) allele 2 was performed by PCR-based amplification followed by restrictive endonuclease digestion. Statistical analyses were conducted by center-, gender group-, and age group-stratified Mantel-Haenszel odds ratios, CI, and p values. RESULTS: The allele frequency of IL-1A(-889) allele 2 was 46% in clinically diagnosed patients with probable AD versus 34% in control subjects from the combined centers. CONCLUSION: The authors found an increased risk for AD with an estimated Mantel-Haenszel odds ratio of 1.68 (95% CI 1.1 to 2.6; p = 0.022) for heterozygous carriers and 7.2 (95% CI 2.0 to 24.5; p = 0.003) for individuals homozygous for IL-1A(-889) allele 2. They found no evidence for an interaction between the IL-1A and the apoE epsilon 4 polymorphisms (carriers and homozygotes), age, or gender with regard to conferred risk. The data strongly support an association between the IL-1A(-889) allele 2, especially in homozygotes, and later-onset AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Moms, J. C., Heyman, A., Mohs, R. C., Hughes, J. P., van Belle, G., Fillenbaum, G., Mellits, E. D., & Clark, C. (1989) · Neurology · doi:10.1212/wnl.39.9.1159 · Cited by 4,130
Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI.
Hixson, J., & Vernier, D. (1990) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)43176-1 · Cited by 2,933
Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease.
Griffin, W. S., Stanley, L. C., Ling, C., White, L., MacLeod, V, Perrot, L. J., White, C. L., & Araoz, C. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.19.7611 · Cited by 1,777
Self-citationMicroglial activation by Alzheimer amyloid precursor protein and modulation by apolipoprotein E
Barger, S. W., & Harmon, A. D. (1997) · Nature · doi:10.1038/42257 · Cited by 622
Microglia in degenerative neurological disease
McGeer, P. L., Kawamata, T., Walker, D. G., Akiyama, H., Tooyama, I., & McGeer, E. G. (1993) · Glia · doi:10.1002/glia.440070114 · Cited by 596
Interleukin‐6 and α‐2‐macroglobulin indicate an acute‐phase state in Alzheimer's disease cortices
Bauer, J., Strauss, S., Schreiter-Gasser, U., Ganter, U., Schlegel, P., Witt, I., Yolk, B., & Berger, M. (1991) · FEBS Letters · doi:10.1016/0014-5793(91)80737-n · Cited by 483
A4POE*4-associated Alzheimer's disease risk is modified by α1–antichymotrypsin polymorphism
Kamboh, M. I., Sanghera, D. K., Ferrell, R. E., & DeKosky, S. T. (1995) · Nature Genetics · doi:10.1038/ng0895-486 · Cited by 336
Sheng, J. G., Ito, K., Skinner, R. D., Mrak, R. E., Rovnaghi, C. R., van Eldik, L. J., & Griffin, W. S. T. (1996) · Neurobiology of Aging · doi:10.1016/0197-4580(96)00104-2 · Cited by 269
Self-citationFarrer, L. A. (1997) · JAMA · doi:10.1001/jama.1997.03550160069041 · Cited by 124
Cited by
A Meta-Analysis of Cytokines in Alzheimer's Disease
Swardfager, W., Lanctôt, K., Rothenburg, L., Wong, A., Cappell, J., & Herrmann, N. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.06.012 · Cited by 1,108
Inflammatory mediators in the elderly
Krabbe, K. S., Pedersen, M., & Bruunsgaard, H. (2004) · Experimental Gerontology · doi:10.1016/j.exger.2004.01.009 · Cited by 928
Inflammation and the Degenerative Diseases of Aging
McGEER, P. L., & McGEER, E. G. (2004) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1332.007 · Cited by 518
Inflammation, autotoxicity and Alzheimer disease
McGeer, P. (2001) · Neurobiology of Aging · doi:10.1016/s0197-4580(01)00289-5 · Cited by 478
Inflammatory processes in Alzheimer's disease
McGeer, E. G., & McGeer, P. L. (2003) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(03)00124-6 · Cited by 472
Molecular mechanisms of aging-associated inflammation
Sarkar, D., & Fisher, P. B. (2006) · Cancer Letters · doi:10.1016/j.canlet.2005.04.009 · Cited by 359
Interleukin-1, neuroinflammation, and Alzheimer's disease
Mrak, R. (2001) · Neurobiology of Aging · doi:10.1016/s0197-4580(01)00287-1 · Cited by 356
Inflammation and neurodegenerative diseases
Griffin, W. S. T. (2006) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/83.2.470s · Cited by 351
Self-citationPatel, N. S., Paris, D., Mathura, V., Quadros, A. N., Crawford, F. C., & Mullan, M. J. (2005) · Journal of Neuroinflammation · doi:10.1186/1742-2094-2-9 · Cited by 319
Chen, J.-H., Lin, K.-P., & Chen, Y.-C. (2009) · Journal of the Formosan Medical Association · doi:10.1016/s0929-6646(09)60402-2 · Cited by 288
Long-term intracerebral inflammatory response after traumatic brain injury
Gentleman, S. M., Leclercq, P. D., Moyes, L., Graham, D. I., Smith, C., Griffin, W. S. T., & Nicoll, J. A. R. (2004) · Forensic Science International · doi:10.1016/j.forsciint.2004.06.027 · Cited by 272
Self-citationMicroglia and neuroprotection: From in vitro studies to therapeutic applications
Polazzi, E., & Monti, B. (2010) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2010.06.009 · Cited by 262
Local Neuroinflammation and the Progression of Alzheimer's Disease
McGeer, P. L., & McGeer, E. G. (2002) · Journal of Neurovirology · doi:10.1080/13550280290100969 · Cited by 255
Monoamine Oxidase-B Inhibition in Alzheimer's Disease
Riederer, P. (2004) · NeuroToxicology · doi:10.1016/s0161-813x(03)00106-2 · Cited by 254
Griffin, W. S. T., & Mrak, R. E. (2002) · Journal of Leukocyte Biology · doi:10.1189/jlb.72.2.233 · Cited by 248
Self-citationHensley, K. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-1414 · Cited by 248
Daglia, M., Lorenzo, A., Nabavi, S., Talas, Z., & Nabavi, S. (2014) · Current Pharmaceutical Biotechnology · doi:10.2174/138920101504140825120737 · Cited by 244
“The data obtained from genetic studies show that polymorphisms of proinflammatory cytokines and α1antichymotrypsin are risk factors of AD [64].”
BackgroundSheng, J. G., Jones, R. A., Zhou, X. Q., McGinness, J. M., Van Eldik, L. J., Mrak, R. E., & Griffin, W. S. T. (2001) · Neurochemistry International · doi:10.1016/s0197-0186(01)00041-9 · Cited by 176
Self-citationBales, K. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00143-3 · Cited by 143
Self-citationNilsson, L. N. G., Bales, K. R., DiCarlo, G., Gordon, M. N., Morgan, D., Paul, S. M., & Potter, H. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-05-01444.2001 · Cited by 137
“Such polymorphisms have been identified in the IL-1 promoter (Du et al., 2000; Grimaldi et al., 2000; Nicoll et al., 2000), the ACT (Kamboh et al., 1995; Yamada et al., 1998), and the ApoE coding regions (Corder et al., 1993; Strittmatter et al., 1993) as well as the ApoE promoter (Bullido et al.,…”
BackgroundSelf-citationNeuroinflammation‐induced acceleration of amyloid deposition in the APPV717F transgenic mouse
Qiao, X., Cummins, D. J., & Paul, S. M. (2001) · European Journal of Neuroscience · doi:10.1046/j.0953-816x.2001.01666.x · Cited by 119
Self-citationNeuroinflammation: a potential therapeutic target
Craft, J. M., Watterson, D. M., & Van Eldik, L. J. (2005) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.9.5.887 · Cited by 116
Interleukins, Inflammation, and Mechanisms of Alzheimer's Disease
Weisman, D., Hakimian, E., & Ho, G. J. (2006) · Vitamins & Hormones · doi:10.1016/s0083-6729(06)74020-1 · Cited by 95
Peripheral Chemo-Cytokine Profiles in Alzheimers and Parkinsons Diseases
Reale, M., Greig, N., & Kamal, M. (2009) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/138955709789055199 · Cited by 82
Complement in Alzheimer's disease: opportunities for modulating protective and pathogenic events
Tenner, A. (2001) · Neurobiology of Aging · doi:10.1016/s0197-4580(01)00301-3 · Cited by 81
APOE epsilon-4 allele and cytokine production in Alzheimer's disease
Olgiati, P., Politis, A., Malitas, P., Albani, D., Dusi, S., Polito, L., De Mauro, S., Zisaki, A., Piperi, C., Stamouli, E., et al. (2010) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.2344 · Cited by 35
“This is in contrast with a large number of studies that demonstrate the influence of TNF-a and IL-1 genes on age at onset (Du et al., 2000; Grimaldi et al., 2000; Rebeck, 2000; Alvarez et al., 2002) and progression of AD (Kolsch et al., 2001; Murphy et al., 2001; Licastro et al., 2004) as well as…”
ResultApolipoprotein E expression is elevated by interleukin 1 and other interleukin 1-induced factors
Liu, L., Aboud, O., Jones, R. A., Mrak, R. E., Griffin, W. S. T., & Barger, S. W. (2011) · Journal of Neuroinflammation · doi:10.1186/1742-2094-8-175 · Cited by 33
Self-citation
Metadata
- Authors
- Du, Y., Dodel, R. C., Eastwood, B. J., Bales, K. R., Gao, F., Lohmüller, F., Müller, U., Kurz, A., Zimmer, R., Evans, R. M., Hake, A., Gasser, T., Oertel, W. H., Griffin, W. S. T., Paul, S. M., & Farlow, M. R.
- Venue
- Neurology
- Published
- 2000-08-22
- Volume
- 55
- Issue
- 4
- Pages
- 480-484
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2164096164
- Cited by
- 195
- References
- 9
- FWCI
- 15.50
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.